Publication:
Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma

Placeholder

Organizational Units

Program

School / College / Institute

GRADUATE SCHOOL OF HEALTH SCIENCES

KU-Authors

KU Authors

Co-Authors

Zwimpfer T.A., Ewald H., Jayawardana M., Appenzeller-Herzog C., Bizzarri N., Razumova Z., Kacperczyk-Bartnik J., Heinzelmann-Schwarz V., Friedlander M., Bowtell D.D.L., Garsed D.W.

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors. Copyright © 2024 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.

Source

Publisher

John Wiley and Sons Ltd

Subject

Medicine

Citation

Has Part

Source

Cochrane Database of Systematic Reviews

Book Series Title

Edition

DOI

10.1002/14651858.CD015896

item.page.datauri

Link

Rights

Rights URL (CC Link)

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details